Background:
Osteoarthritis (OA) is one of the most prevalent musculoskeletal conditions, affecting 7.96% of the global population in 2020. It is associated with substantial morbidity, increased healthcare costs, and elevated lifetime risk. Accumulating evidence suggests that metabolic disorders-including insulin resistance, dyslipidemia, and chronic low-grade inflammation-play a critical role in the pathogenesis and progression of OA. This phenotype is often referred to as metabolic osteoarthritis (Metabolic OA). Moreover, individuals with metabolic dysfunction may be at increased risk of complications following joint arthroplasty, such as prosthetic joint infection (PJI), impaired wound healing, and delayed recovery. Investigating the relationship between metabolic health and musculoskeletal outcomes may provide valuable insights for risk stratification, improved perioperative care, and targeted therapeutic approaches.
Objective:
To evaluate the associations between metabolic dysfunction and both the risk of osteoarthritis and postoperative complications following joint arthroplasty.